It currently operates in the Australasian healthcare markets where it specialises in advanced screening technologies. In principle this negates the need for preliminary diagnoses to be carried out through doctors and laboratories, instead this unique system of testing/screening, can be adequately carried out in the home or by the health professional in a pharmacy. There are evidential benefits to
be gained from this, including earlier diagnosis of a medical condition, more efficient use of doctors time, less inconvenience for the client and less overall cost. Smith BioMed is the leader in this field with ready access to the latest developments in global pharmaceutical research and from manufacturing organisations. Included in this range of technologies is the access to rapid on-site forensic screening for the latest menu of drugs of abuse. This is an essential and valuable component in the battle to contain the continuing spread of drug addiction, accepted as endemic in many parts of the world. Smith Biomed was founded in 2002, primarily to take advantage of the growing trend in USA and Europe of using rapid on site disposable tests for the detection of drugs of abuse in both urine and saliva. This method of testing improved the efficacy of screening in the workplace and as a consequence, the health and safety of employees. In addition there developed some staggering improvements in the productivity of industry in general. Since then we have moved into the area of point of care medical diagnostics. This was a natural progression since the design structure of these medical disposable devices is similar in character to the on-site disposable drug and alcohol tests. The main benefits of medical diagnostic testing are early diagnosis, convenience and overall cost.
